| Variables |
Total (N, %) |
Dead (N, %) |
Active (N, %) |
Log-rank P |
| Functional status |
|
|
|
0.000 |
| Working |
434 (55.4%) |
12 (13.8%) |
422 (60.5%) |
| Ambulatory |
242 (30.9%) |
37 (42.5%) |
205 (29.4%) |
| Bedridden |
108 (13.8%) |
38 (43.7%) |
70 (10.0%) |
| WHO staging |
|
|
|
0.000 |
| Stage I & II |
329 (42.0%) |
10 (11.5%) |
319 (45.8%) |
| Stage III |
327 (41.7%) |
38 (43.7%) |
289 (41.5%) |
| Stage IV |
128 (16.3%) |
39 (44.8%) |
89 (12.8%) |
| BMI for age |
|
|
|
0.000 |
| ≥18.5 Kg/m2 |
335 (42.7%) |
23 (26.4%) |
312 (44.8%) |
| < 18.5 Kg/m2 |
449 (57.3%) |
64 (73.6%) |
385 (55.2%) |
| ART regimen |
|
|
|
0.429 |
| d4T/3TC/NVP |
221 (28.2%) |
25 (28.7%) |
196 (28.1%) |
| d4T/3TC/EFV |
78 (9.9%) |
7 (8.0%) |
71 (10.2%) |
| AZT/3TC/NVP |
202 (25.8%) |
25 (28.7%) |
177 (25.4%) |
| AZT/3TC/EFV |
50 (6.4%) |
5 (5.7%) |
45 (6.5%) |
| TDF/3TC/EFV |
118 (15.1%) |
10 (11.5%) |
108 (15.5%) |
| TDF/3TC/NVP |
115 (14.7%) |
15 (17.2%) |
100 (14.3%) |
| Cotrimoxazole |
|
|
|
0.032 |
| Given |
658 (83.9%) |
66 (75.9%) |
592 (84.9%) |
| Not given |
126 (16.1%) |
21 (24.1%) |
105 (15.1%) |
| INH Given |
|
|
|
0.000 |
| Given |
61 (7.8%) |
20 (23.0%) |
41 (5.9%) |
| Not given |
723 (92.2%) |
67 (77.0%) |
656 (98.3%) |
| TB co-infected |
|
|
|
0.015 |
| Yes |
311 (39.7%) |
45 (51.7%) |
266 (38.2%) |
| No |
473 (60.3%) |
42 (48.3%) |
431 (61.8%) |
| Weight (Kg) ‡ |
49.9 (44−56) |
43.8 (37−50) |
50.7 (45−56) |
0.000 |
| CD4 count (cells/ μL) ‡ |
150 (102−196) |
72 (31−99) |
160 (116−206) |
0.000 |
| Hemoglobin (g/dL) ‡& |
11.4 (10.0−13.0) |
9.9 (7.9−11.3) |
11.6 (10.3−13.1) |
0.000 |
|
